Find Bosentan Hydrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 147536-97-8, Tracleer, Actelion, Bosentan anhydrous, Ro 47-0203, Ro-47-0203
Molecular Formula
C27H29N5O6S
Molecular Weight
551.6  g/mol
InChI Key
GJPICJJJRGTNOD-UHFFFAOYSA-N
FDA UNII
XUL93R30K2

Bosentan Hydrate
A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.
Bosentan anhydrous is an Endothelin Receptor Antagonist. The mechanism of action of bosentan anhydrous is as an Endothelin Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2C9 Inducer.
1 2D Structure

Bosentan Hydrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
2.1.2 InChI
InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
2.1.3 InChI Key
GJPICJJJRGTNOD-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC
2.2 Other Identifiers
2.2.1 UNII
XUL93R30K2
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-t-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide

2. Bosentan Anhydrous

3. Bosentan Monohydrate

4. Ro 47 0203

5. Ro 47-0203

6. Ro 470203

7. Ro-47-0203

8. Tracleer

2.3.2 Depositor-Supplied Synonyms

1. 147536-97-8

2. Tracleer

3. Actelion

4. Bosentan Anhydrous

5. Ro 47-0203

6. Ro-47-0203

7. Anhydrous Bosentan

8. Bosentan [usan:inn:ban]

9. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide

10. P-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide

11. Bosentan (inn)

12. 4-(tert-butyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide

13. Chembl957

14. Xul93r30k2

15. N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide

16. Chebi:51450

17. 147536-97-8 (free)

18. 174227-18-0

19. Benzenesulfonamide, 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-

20. Ncgc00167440-01

21. Bosentan [inn]

22. Dsstox_cid_26627

23. Dsstox_rid_81776

24. Dsstox_gsid_46627

25. 1174918-31-0

26. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) Benzenesulfornamide

27. 4-tert-butyl-n-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide

28. Benzenesulfonamide, 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-

29. Bosentanum

30. Ro-47-0203/029

31. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide

32. Cas-147536-97-8

33. Ro 47-0203/039

34. Sr-05000001532

35. Ro-470203029

36. Ro-47-0203-029

37. Unii-xul93r30k2

38. 4-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide

39. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide

40. Ks-5062

41. Starbld0043886

42. Bosentan [mi]

43. Ro-47-0203/039

44. Bosentan [who-dd]

45. Schembl4218

46. Gtpl3494

47. Dtxsid7046627

48. Hms2090n14

49. Hms3652f15

50. Hms3715n05

51. Hms3750a13

52. Bcp05202

53. Hy-a0013

54. Zinc1538857

55. Tox21_112444

56. Ac-148

57. Bdbm50061101

58. Pdsp1_001731

59. Pdsp2_001714

60. S4220

61. Akos015852063

62. Tox21_112444_1

63. Am84442

64. Bcp9000445

65. Ccg-221182

66. Cs-0381

67. Db00559

68. Sb17356

69. Ncgc00167440-02

70. Bb164259

71. B5118

72. Ft-0658809

73. Sw199648-3

74. D07538

75. W18800

76. Ab01275536-01

77. 212b550

78. A808658

79. L001086

80. Q419769

81. J-008366

82. Sr-05000001532-1

83. Sr-05000001532-2

84. Sr-05000001532-4

85. Z1541632805

86. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2''-bipyrimidin)-4-yl) Benzenesulfornamide

87. 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide

88. 4-(tert-butyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide

89. 4-tert Butyl-n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]benzenesulphonamide

90. 4-tert-butyl-n-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-benzenesulfonamide

91. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-4-yl]benzene-1-sulfonamide

92. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2''-bipyrimidin-4-yl]benzenesulfonamide

93. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide

94. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide

95. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide

96. K86

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 551.6 g/mol
Molecular Formula C27H29N5O6S
XLogP33.8
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count11
Rotatable Bond Count11
Exact Mass551.18385484 g/mol
Monoisotopic Mass551.18385484 g/mol
Topological Polar Surface Area154 Ų
Heavy Atom Count39
Formal Charge0
Complexity839
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameTracleer
PubMed HealthBosentan (By mouth)
Drug ClassesAntihypertensive
Drug LabelTracleer is the proprietary name for bosentan, an endothelin receptor antagonist that belongs to a class of highly substituted pyrimidine derivatives, with no chiral centers. It is designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-me...
Active IngredientBosentan
Dosage FormTablet
RouteOral
Strength125mg; 62.5mg
Market StatusPrescription
CompanyActelion Pharms

2 of 2  
Drug NameTracleer
PubMed HealthBosentan (By mouth)
Drug ClassesAntihypertensive
Drug LabelTracleer is the proprietary name for bosentan, an endothelin receptor antagonist that belongs to a class of highly substituted pyrimidine derivatives, with no chiral centers. It is designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-me...
Active IngredientBosentan
Dosage FormTablet
RouteOral
Strength125mg; 62.5mg
Market StatusPrescription
CompanyActelion Pharms

4.2 Drug Indication

Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).


FDA Label


Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

- Primary (idiopathic and familial) PAH;

- PAH secondary to scleroderma without significant interstitial pulmonary disease;

- PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology.

Some improvements have also been shown in patients with PAH WHO functional class II.

Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.


5.2 MeSH Pharmacological Classification

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)


Endothelin Receptor Antagonists

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS. (See all compounds classified as Endothelin Receptor Antagonists.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
BOSENTAN ANHYDROUS
5.3.2 FDA UNII
XUL93R30K2
5.3.3 Pharmacological Classes
Cytochrome P450 3A Inducers [MoA]; Endothelin Receptor Antagonist [EPC]; Endothelin Receptor Antagonists [MoA]; Cytochrome P450 2C9 Inducers [MoA]
5.4 ATC Code

C02KX01


C02KX01

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


C - Cardiovascular system

C02 - Antihypertensives

C02K - Other antihypertensives

C02KX - Antihypertensives for pulmonary arterial hypertension

C02KX01 - Bosentan


5.5 Absorption, Distribution and Excretion

Absorption

Absolute bioavailability is approximately 50% and food does not affect absorption.


Route of Elimination

Bosentan is eliminated by biliary excretion following metabolism in the liver.


Volume of Distribution

18 L


Clearance

4 L/h [patients with pulmonary arterial hypertension]


5.6 Metabolism/Metabolites

Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.


Bosentan has known human metabolites that include 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2-]bipyrimidinyl-4-yl]-benzenesulfonamide and Hydroxy Bosentan.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

Terminal elimination half-life is about 5 hours in healthy adult subjects.


5.8 Mechanism of Action

Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. It displays a slightly higher affinity towards ETA receptors than ETB receptors. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB.


DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - 125MG

USFDA APPLICATION NUMBER - 21290

read-more

DOSAGE - TABLET;ORAL - 62.5MG

USFDA APPLICATION NUMBER - 21290

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Direct Compression

read-more
read-more

Lubricants & Glidants

read-more
read-more

Granulation

read-more
read-more

Co-Processed Excipients

read-more
read-more

Taste Masking

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Empty Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Vegetarian Capsules

read-more
read-more

Emulsifying Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Solubilizers

read-more
read-more

Coloring Agents

read-more
read-more

Parenteral

read-more
read-more

Topical

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 147536-97-8 / Bosentan Hydrate API manufacturers, exporters & distributors?

Bosentan Hydrate manufacturers, exporters & distributors 1

37

PharmaCompass offers a list of Bosentan Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bosentan Hydrate manufacturer or Bosentan Hydrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bosentan Hydrate manufacturer or Bosentan Hydrate supplier.

PharmaCompass also assists you with knowing the Bosentan Hydrate API Price utilized in the formulation of products. Bosentan Hydrate API Price is not always fixed or binding as the Bosentan Hydrate Price is obtained through a variety of data sources. The Bosentan Hydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Bosentan Hydrate

Synonyms

147536-97-8, Tracleer, Actelion, Bosentan anhydrous, Ro 47-0203, Ro-47-0203

Cas Number

147536-97-8

Unique Ingredient Identifier (UNII)

XUL93R30K2

About Bosentan Hydrate

A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.

Bosentan Hydrate Manufacturers

A Bosentan Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bosentan Hydrate, including repackagers and relabelers. The FDA regulates Bosentan Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bosentan Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Bosentan Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Bosentan Hydrate Suppliers

A Bosentan Hydrate supplier is an individual or a company that provides Bosentan Hydrate active pharmaceutical ingredient (API) or Bosentan Hydrate finished formulations upon request. The Bosentan Hydrate suppliers may include Bosentan Hydrate API manufacturers, exporters, distributors and traders.

click here to find a list of Bosentan Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Bosentan Hydrate USDMF

A Bosentan Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Bosentan Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Bosentan Hydrate DMFs exist exist since differing nations have different regulations, such as Bosentan Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Bosentan Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Bosentan Hydrate USDMF includes data on Bosentan Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bosentan Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Bosentan Hydrate suppliers with USDMF on PharmaCompass.

Bosentan Hydrate JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Bosentan Hydrate Drug Master File in Japan (Bosentan Hydrate JDMF) empowers Bosentan Hydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Bosentan Hydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Bosentan Hydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Bosentan Hydrate suppliers with JDMF on PharmaCompass.

Bosentan Hydrate KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Bosentan Hydrate Drug Master File in Korea (Bosentan Hydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Bosentan Hydrate. The MFDS reviews the Bosentan Hydrate KDMF as part of the drug registration process and uses the information provided in the Bosentan Hydrate KDMF to evaluate the safety and efficacy of the drug.

After submitting a Bosentan Hydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Bosentan Hydrate API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Bosentan Hydrate suppliers with KDMF on PharmaCompass.

Bosentan Hydrate WC

A Bosentan Hydrate written confirmation (Bosentan Hydrate WC) is an official document issued by a regulatory agency to a Bosentan Hydrate manufacturer, verifying that the manufacturing facility of a Bosentan Hydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bosentan Hydrate APIs or Bosentan Hydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Bosentan Hydrate WC (written confirmation) as part of the regulatory process.

click here to find a list of Bosentan Hydrate suppliers with Written Confirmation (WC) on PharmaCompass.

Bosentan Hydrate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bosentan Hydrate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Bosentan Hydrate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Bosentan Hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Bosentan Hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bosentan Hydrate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Bosentan Hydrate suppliers with NDC on PharmaCompass.

Bosentan Hydrate GMP

Bosentan Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Bosentan Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bosentan Hydrate GMP manufacturer or Bosentan Hydrate GMP API supplier for your needs.

Bosentan Hydrate CoA

A Bosentan Hydrate CoA (Certificate of Analysis) is a formal document that attests to Bosentan Hydrate's compliance with Bosentan Hydrate specifications and serves as a tool for batch-level quality control.

Bosentan Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Bosentan Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Bosentan Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Bosentan Hydrate EP), Bosentan Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bosentan Hydrate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty